Search
Centanafadine
go.drugbank.com/drugs/DB14841ApprovedInvestigationalCentanafadine is a reuptake inhibitor at the norepinephrine, dopamine, and serotonin transporters and a central nervous system stimulant. … reuptake inhibitor, positioning it as a new mechanistic option in a condition where response varies widely between individuals and many patients remain symptomatic on existing treatment.
Filgotinib
go.drugbank.com/drugs/DB14845ApprovedInvestigationalIn contrast, the newly approved filgotinib is a highly selective JAK1 inhibitor. … Rheumatoid arthritis (RA) is a chronic, autoimmune, systemic, and inflammatory disease that causes synovial joint symptoms and can limit range of motion in severe cases.
Categories: P-glycoprotein substrates, Heterocyclic Compounds, 1-RingOliceridine
go.drugbank.com/drugs/DB14881ApprovedInvestigational[A218041] Oliceridine gained FDA approval on August 7, 2020, and is currently marketed by Trevena Inc as OLINVYK™.[L15516] … [A218026, A218031, A218036, A218041, A218046] Oliceridine (formerly known as TRV130) is a "biased agonist" at the μ-opioid receptor by preferentially activating the G-protein pathway with minimal receptor
Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 1-RingSynonyms: 奥赛利定Imetelstat
go.drugbank.com/drugs/DB14909ApprovedInvestigationalImetelstat is a first-in-class 18-amino acid oligonucleotide that directly and competitively inhibits human telomerase. … cell morphology and a risk for transformation to acute myeloid leukemia.
Mavacamten
go.drugbank.com/drugs/DB14921ApprovedInvestigationalIt received initial US FDA approval in 2022, and it is one of the first myosin inhibitors to be used in humans. … Mavacamten is a myosin inhibitor indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM).
Categories: Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 SubstratesSynonyms: 6-(((1S)-1-Phenylethyl)amino)-3-(propan-2-yl)-1,2,3,4 tetrahydropyrimidine-2,4-dioneMotixafortide
go.drugbank.com/drugs/DB14939ApprovedInvestigational[L48136] Similar in mechanism to the previously approved [plerixafor], motixafortide is an inhibitor of C-X-C Motif Chemokine Receptor 4 (CXCR4), a protein that helps to anchor stem cells to bone marrow … Motixafortide is a cyclic peptide hematopoietic stem cell mobilizer used to improve stem cell collection prior to autologous transplantation.
Venglustat
go.drugbank.com/drugs/DB14966InvestigationalVenglustat is under investigation in clinical trial NCT01674036 (Safety, Tolerability and Pharmacokinetics of Genz-682452 in Healthy Men).
Umbralisib
go.drugbank.com/drugs/DB14989ApprovedInvestigationalWithdrawnMarginal zone lymphoma is a rare, slowly progressing type of non-Hodgkin lymphoma initially treated with [rituximab] (an anti-CD20 drug), either alone or in combination with chemotherapy. … with a possible increased risk of death outweighing the benefits.
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesBrepocitinib
go.drugbank.com/drugs/DB15003ApprovedInvestigationalBrepocitinib is an oral Janus kinase (JAK) and tyrosine kinase 2 (TYK2) inhibitor used to treat dermatomyositis in adults. … [L64097] Brepocitinib is not recommended in combination with other JAK inhibitors, other TYK2 inhibitors, or biologic DMARDs.
Categories: MATE 1 Inhibitors, MATE 2 InhibitorsRogaratinib
go.drugbank.com/drugs/DB15078InvestigationalRogaratinib is under investigation in clinical trial NCT03762122 (Rogaratinib in Patients With Advanced Pretreated Squamous-cell Non-small Cell Lung Cancer (SQCLC)).
Categories: Heterocyclic Compounds, 1-Ring